BR0316111A - Métodos para diagnosticar rcc e outros tumores sólidos - Google Patents

Métodos para diagnosticar rcc e outros tumores sólidos

Info

Publication number
BR0316111A
BR0316111A BR0316111A BR0316111A BR0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A
Authority
BR
Brazil
Prior art keywords
solid tumors
methods
rcc
ccr
genes
Prior art date
Application number
BR0316111A
Other languages
English (en)
Inventor
Natalie Constance Twine
Michael E Burczynski
William L Trepicchio
Andrew Dorner
Jennifer A Stover
Donna K Slonim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0316111A publication Critical patent/BR0316111A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

"MéTODOS PARA DIAGNOSTICAR RCC E OUTROS TUMORES SóLIDOS". Métodos, sistemas e equipamentos para diagnosticar o carcinoma de células renais (RCC) e outros tumores sólidos. Esta invenção identifica numerosos genes doentios que são diferencialmente expressos no sangue periférico de pacientes tendo RCC ou outros tumores sólidos em relação aos seres humanos livres de doença. Estes genes doentios podem ser usados como marcadores substitutos para detectar a presença ou ausência de RCC ou outros tumores sólidos.
BR0316111A 2002-11-21 2003-11-21 Métodos para diagnosticar rcc e outros tumores sólidos BR0316111A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42798202P 2002-11-21 2002-11-21
US45978203P 2003-04-03 2003-04-03
PCT/US2003/037481 WO2004048933A2 (en) 2002-11-21 2003-11-21 Methods for diagnosing rcc and other solid tumors

Publications (1)

Publication Number Publication Date
BR0316111A true BR0316111A (pt) 2005-09-13

Family

ID=32397089

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316111A BR0316111A (pt) 2002-11-21 2003-11-21 Métodos para diagnosticar rcc e outros tumores sólidos

Country Status (8)

Country Link
US (1) US7611839B2 (pt)
EP (1) EP1588142A4 (pt)
JP (1) JP2006514554A (pt)
AU (1) AU2003298689A1 (pt)
BR (1) BR0316111A (pt)
CA (1) CA2505416A1 (pt)
MX (1) MXPA05005283A (pt)
WO (1) WO2004048933A2 (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US8008012B2 (en) * 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
US9895413B2 (en) 2002-11-13 2018-02-20 Board Of Regents, University Of Texas System Protection against and treatment of ionizing radiation
US20050123594A1 (en) * 2002-11-13 2005-06-09 Sanjay Awasthi Liposomes for protection against toxic compounds
US20060182749A1 (en) * 2002-11-13 2006-08-17 Board Of Regents, The University Of Texas System Therapies for cancer using RLIP76
US8163692B2 (en) * 2002-11-13 2012-04-24 University Of North Texas Health Science Center Of Fort Worth Protection against and treatment of ionizing radiation
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
CA2514058C (en) 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
AU2004210986A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
AU2004235395A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
CA2555199A1 (en) * 2004-02-04 2005-08-18 Yokohama City University Peptidylarginine deiminase 4 inhibitor
WO2006002240A2 (en) * 2004-06-19 2006-01-05 Chondrogene, Inc. Computer systems and methods for constructing biological classifiers and uses thereof
US7991557B2 (en) * 2004-06-19 2011-08-02 Genenews Corporation Computer system and methods for constructing biological classifiers and uses thereof
US8080373B2 (en) * 2004-08-03 2011-12-20 Bauer Jr A Robert Method for the early detection of pancreatic cancer and other gastrointestinal disease conditions
US20080280282A1 (en) * 2004-08-03 2008-11-13 Bauer Jr A Robert Method for early detection of various cancers and gastrointestinal disease and monitoring of transplanted organs
US20060094018A1 (en) * 2004-08-03 2006-05-04 Bauer A R Jr Discovery and a method for the early detection of pancreatic cancer and other disease conditions
US7820382B2 (en) 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
EP1846576A4 (en) * 2005-02-01 2009-01-07 Us Gov Health & Human Serv BIOMARKERS OF TISSUE STATUS
WO2006097388A2 (en) * 2005-02-08 2006-09-21 Innogenetics N.V. Nucleic acid variants in the c1qr1 gene associated with altered innate immunity.
RU2007129864A (ru) * 2005-02-18 2009-03-27 Вайет (Us) Фармакогеномные маркеры для прогнозирования солидных опухолей
EP1875246B1 (en) * 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
EP2386654A1 (en) * 2005-05-02 2011-11-16 University of Southern California DNA Methylation markers associated with the CpG island methylator phenotype (cimp) in human colorectal cancer
JP5435529B2 (ja) 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
JPWO2007099852A1 (ja) * 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2008086502A2 (en) * 2007-01-10 2008-07-17 University Of Chicago Molecular marker for clear renal cell carcinoma
ES2608803T3 (es) 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
CN101960309A (zh) 2008-01-17 2011-01-26 东丽株式会社 用于肾癌诊断或检测的组合物及方法
MX340916B (es) * 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
WO2009100446A1 (en) * 2008-02-07 2009-08-13 Terapio, Llc Compositions for delivery of cargo such as drugs proteins and/or genetic materials
GB0803464D0 (en) * 2008-02-26 2008-04-02 Medical Res Council Methods and compositions
DE102008031699A1 (de) * 2008-07-04 2010-01-14 Protagen Ag Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung
EP2329040B1 (en) * 2008-09-22 2017-10-11 ADVPharma, Inc. Molecular markers for lung and colorectal carcinomas
WO2010048347A2 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
KR101087617B1 (ko) * 2009-03-19 2011-11-29 한국생명공학연구원 Ｅｎｉｇｍａ―Ｍｄｍ２ 상호작용 및 그 용도
JP5940976B2 (ja) * 2009-07-24 2016-06-29 テラピオ コーポレイション 放射線照射後防護のための組成物および使用の方法
CN102576028A (zh) 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
RU2012157998A (ru) 2010-06-01 2014-07-20 Тодос Медикал Лтд. Диагностика рака
US20110301110A1 (en) * 2010-06-03 2011-12-08 Aucagne Romain TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
WO2012153326A1 (en) 2011-05-11 2012-11-15 Todos Medical Ltd. Diagnosis of cancer
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
WO2013123026A1 (en) 2012-02-13 2013-08-22 Terapio Corporation Rlip76 as a medical chemical countermeasure
US9493810B2 (en) 2012-06-07 2016-11-15 Pioma, Inc. 5-ALA for detection of brain tumors
WO2014003580A1 (en) * 2012-06-28 2014-01-03 Caldera Health Ltd Targeted rna-seq methods and materials for the diagnosis of prostate cancer
HRP20190303T1 (hr) 2012-10-31 2019-05-17 Ionis Pharmaceuticals, Inc. Liječenje raka
WO2014077915A1 (en) * 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2014164362A1 (en) * 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
WO2014164365A1 (en) * 2013-03-09 2014-10-09 Harry Stylli Methods of detecting head and neck cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
ES2877332T3 (es) 2013-05-28 2021-11-16 Todos Medical Ltd Un método para indicar la presencia de tumores benignos mediante el uso de una muestra de células mononucleares de sangre periférica (PBMC)
MX369911B (es) 2013-05-30 2019-11-26 Genomic Health Inc Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
WO2015042163A1 (en) 2013-09-17 2015-03-26 Terapio Corporation Methods of preventing or treating mucositis using rlip76
US9611304B2 (en) * 2014-05-29 2017-04-04 The University Of British Columbia TNNT1 mini-promoters
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
WO2016031816A1 (ja) 2014-08-26 2016-03-03 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
EP3067698A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer
WO2017132169A1 (en) * 2016-01-28 2017-08-03 Siemens Healthcare Diagnostics Inc. Methods and apparatus for detecting an interferent in a specimen
JP6976257B2 (ja) 2016-01-28 2021-12-08 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドSiemens Healthcare Diagnostics Inc. マルチビューの特徴付けのための方法及び装置
AU2017261688B2 (en) 2016-05-10 2022-09-29 Mayo Foundation For Medical Education And Research Methods and materials for staging and treating skin cancer
WO2018067020A1 (en) * 2016-10-05 2018-04-12 Institute Of Environmental Science And Research Limited Rna sequences for body fluid identification
WO2019027693A1 (en) * 2017-07-31 2019-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education AUTOMATIC AND EARLY DETECTION SYSTEM FOR FREE SHUTTLE
CN113039289B (zh) 2018-07-25 2025-11-07 斯凯莱恩迪艾克斯有限公司 预测黑色素瘤转移和患者预后的基因特征
WO2020081956A1 (en) * 2018-10-18 2020-04-23 Medimmune, Llc Methods for determining treatment for cancer patients
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
EP4440626A4 (en) * 2021-12-02 2025-09-17 Childrens Medical Ct Corp GENE THERAPY FOR SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD)
WO2024192027A1 (en) * 2023-03-12 2024-09-19 Novelna Inc. Kidney cancer detection proteins and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5840506A (en) 1996-06-05 1998-11-24 Thomas Jefferson University Methods for the diagnosis and prognosis of cancer
US5919638A (en) 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
US6303301B1 (en) 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6063028A (en) 1997-03-20 2000-05-16 Luciano; Joanne Sylvia Automated treatment selection method
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6087098A (en) 1997-04-15 2000-07-11 The Trustees Of Columbia University In The City Of New York Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma
US6420108B2 (en) * 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
US20030083272A1 (en) 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
US20030104371A1 (en) 1997-09-24 2003-06-05 Strom Terry B. Methods of evaluating transplant rejection
FR2771422B1 (fr) 1997-11-21 2001-07-27 Centre Nat Rech Scient Reactifs et methodes pour la detection de genes lies au complexe majeur d'histocompatibilite d'oiseaux d'elevage, tels que le poulet
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP3944996B2 (ja) 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
KR20070118315A (ko) 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020168638A1 (en) 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
KR20020097198A (ko) 2000-03-17 2002-12-31 베니텍 오스트레일리아 리미티드 유전자 사일런싱
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
US20020042072A1 (en) 2000-06-26 2002-04-11 Jacobus Van Meel Method for monitoring the effect of cancer therapies
AU2001277959A1 (en) 2000-07-21 2002-02-05 Incyte Genomics, Inc. Human kinases
AU2001292870A1 (en) 2000-09-21 2002-04-02 Incyte Genomics, Inc. Protein phosphatases
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
DE10057894A1 (de) * 2000-11-22 2002-06-06 Adnagen Gmbh Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs
BR0115689A (pt) 2000-11-28 2004-02-10 Wyeth Corp Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
WO2002075314A2 (en) 2000-11-30 2002-09-26 Matritech, Inc. Detection and treatment of prostate cancer
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
EP1442062A4 (en) 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US20050287532A9 (en) 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
AU2004210986A1 (en) 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
AU2004235395A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors

Also Published As

Publication number Publication date
EP1588142A4 (en) 2007-10-31
CA2505416A1 (en) 2004-06-10
AU2003298689A1 (en) 2004-06-18
EP1588142A2 (en) 2005-10-26
US20040110221A1 (en) 2004-06-10
WO2004048933A3 (en) 2005-11-10
US7611839B2 (en) 2009-11-03
MXPA05005283A (es) 2005-07-25
JP2006514554A (ja) 2006-05-11
WO2004048933A2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
BR0316111A (pt) Métodos para diagnosticar rcc e outros tumores sólidos
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2006081473A3 (en) Methods for diagnosis and prognosis of epithelial cancers
EP1578923A4 (en) SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES
ATE400813T1 (de) Tumormarker für frühes krebsstadium
EP1363920A4 (en) MODIFIED PSMA LIGANDS AND THEIR USE
DE60016467D1 (de) Ct-systeme zur klinischen überprüfung
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
WO2004066808A3 (en) Glycan markers for diagnosing and monitoring disease
WO2006093507A3 (en) Methods and systems for predicting cancer outcome
DE602006008774D1 (de) Kanüleneinführungssystem
GB9810040D0 (en) Blood borne tumour markers
NO20072296L (no) Fremgangsmater og systemer for prognose og behandling av faste tumorer
BRPI0214840B8 (pt) métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
NL1020758A1 (nl) Werkwijze voor computertomografie alsmede computertomografie(CT-)apparaat.
WO2007088492A3 (en) Improved radiation therapy planning procedure
WO2001031579A3 (en) Methods and devices for identifying patterns in biological patterns
DE60026150D1 (de) Diagnostika und therapeutika für osteoporose
DE10292329D2 (de) Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
EP1451552A4 (en) FOR DETECTING DISORDERS OF BREAST SUITABLE REAGENTS AND METHODS
ATE242642T1 (de) Kombinationstherapie für lymphoproliferative krankheiten
DE69906284D1 (de) Diagnostisches verfahren basierend auf der quantifizierung extramitochondrialer dna
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
BR0111726A (pt) Derivados de biotina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]